The 2017 Global Burden of Disease (GBD) Study captured and summarized data from 1990 to 2016 on death and disability for over 350 diseases and injuries across 195 countries; it also included the analysis of 84 risk factors for which evidence of a causal risk-condition relationship exists. The study includes analysis of chronic kidney disease (CKD; based on the international classification of diseases (ICD) coding of hospitalization and mortality) and of impaired kidney function (IKF; defined as the proportion of the population with albumin to creatinine ratio (ACR) >30 mg/g or estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m 2 , excluding endstage renal disease) as a risk factor for key non-communicable diseases (NCDs), notably cardiovascular disease and CKD. Analyses of the main burdens attributed to CKD and IKF in 2007-2017 show a significant rise of at least 20% in absolute levels for every CKD metric 1-4 (Table 1) . However, CKD age-standardized rates, which adjust for population growth and ageing, were generally stable. Using absolute counts, CKD ranks in the top 30 of all diseases for several metrics and moved up in ranking for mortality and disabilityadjusted life years (DALYs, a composite of from ~26 million in 2016 to 52.5 million in 2040, and deaths will rise from 1.2 million in 2016 to 3.1 million in 2040 (ReF. 5 ). These increases are predicted to move CKD in the YLL rankings from 16th in 2016 to 5th in 2040, a change thought to be mainly driven by population growth and ageing, although the modelling assumptions are complex 5 . It is possible that mortality or YLL attri butable to CKD may be underestimated in these analyses, given the underuse of CKD codes on death certification, which has implications for the reliability of modelling future YLL trajectories.
The 2017 Global Burden of Disease (GBD) Study captured and summarized data from 1990 to 2016 on death and disability for over 350 diseases and injuries across 195 countries; it also included the analysis of 84 risk factors for which evidence of a causal risk-condition relationship exists. The study includes analysis of chronic kidney disease (CKD; based on the international classification of diseases (ICD) coding of hospitalization and mortality) and of impaired kidney function (IKF; defined as the proportion of the population with albumin to creatinine ratio (ACR) >30 mg/g or estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m 2 , excluding endstage renal disease) as a risk factor for key non-communicable diseases (NCDs), notably cardiovascular disease and CKD. Analyses of the main burdens attributed to CKD and IKF in 2007-2017 show a significant rise of at least 20% in absolute levels for every CKD metric [1] [2] [3] [4] ( Table 1) . However, CKD age-standardized rates, which adjust for population growth and ageing, were generally stable. Using absolute counts, CKD ranks in the top 30 of all diseases for several metrics and moved up in ranking for mortality and disabilityadjusted life years (DALYs, a composite of from ~26 million in 2016 to 52.5 million in 2040, and deaths will rise from 1.2 million in 2016 to 3.1 million in 2040 (ReF. 5 ). These increases are predicted to move CKD in the YLL rankings from 16th in 2016 to 5th in 2040, a change thought to be mainly driven by population growth and ageing, although the modelling assumptions are complex 5 . It is possible that mortality or YLL attri butable to CKD may be underestimated in these analyses, given the underuse of CKD codes on death certification, which has implications for the reliability of modelling future YLL trajectories.
One GBD study analysed four key CKD risk factors: dietary sodium, fasting glucose, body mass index (BMI) and systolic blood pressure (SBP) 4 . The last three of these meta bolic risk factors were in the top five of absolute contributions to all DALYs 4 . Between 1990 and 2017, overall SEV of BMI increased by 70% and that of high fasting glucose by 38%, whereas the overall SEV of high SBP decreased by 2%. In absolute terms, the CKD DALYs attributed to high sodium, high fasting glucose, high BMI and high SBP were 3,400,000, 20,620,000, 9,530,000 and 17,490,000, respectively. There were considerable absolute percentage increases for all of these CKD risk factors since 2007 -highest for BMI at over 40% -but percentage changes in age-standardized rates were much smaller, generally <5%, except for BMI 4 . Certain regions are experiencing a dramatic increase in CKD burden 6 , including Oceania, South Asia, East Asia, the Caribbean, Central and Tropical Latin America, North Africa and the Middle East In terms of all-age DALY rate, Central Latin America shows the most concerning increase and this trend is only partly attenuated by age-standardization 3 . Death rates attributed to CKD show a similar pattern in these regions, as does the contribution of IKF as an NCD risk factor 4 . Middle sociodemographic index (SDI) regions are experiencing greater increases in deaths attributed to CKD and greater importance of IKF as a risk factor for NCDs than those with low or high SDI. Of note, whereas global GBD analyses break down by gender, socioeconomic factors are only examined at country level using SDI, and there is no analysis by major ethnic groups. Similar increases are seen for CKD related to T2DM, particularly in South and East Asia, years of life lost (YLL, a metric of mortality) and years lived with disability (YLD)) 3 . Of note, global absolute CKD prevalence increased by 28.2% from 2007-2017 among females and 25.4% among males, whereas the increases in age-standardized rates were 3.0% and 1.1%, respectively 1 . The age-standardized prevalence of IKF was also presented as the summary exposure value (SEV), which was stable for males but increased slightly (1.7%) in females 4 . Arguably, one of the most important measures presented is the DALY, which allows comparison with other disease states and incorporates both death and disability but requires assumptions to be made about disease severity and disability weights. Both the CKD burden by absolute count and by all-age DALY rate, which adjusts for population growth, are increasing globally and this is reflected in the contribution of IKF to the NCD DALY burden 3, 4 . Age-standardized CKD DALY rates have not increased. CKD due to type 2 diabetes mellitus (T2DM) represented the second largest increase in DALYs for all conditions analysed (34.3%) between 2007 and 2017 (ReF. A forecasting analysis suggests that the number of global YLL due to CKD will increase The analyses in the 2017 Global Burden of Disease Study demonstrate the growing burden of chronic kidney disease (CKD), mainly driven by population ageing; absolute levels for every CKD metric considered rose significantly , whereas age-standardized rates were fairly stable. The prevalence of key metabolic CKD risk factors, particularly obesity , also show a worrying increase. The GBD study has important limitations. Methods for generating the diverse metrics globally and by time period, country, region and person are complex and difficult to fully appraise. Moreover, the sources of data used by GBD analyses are increasing rapidly but considerable assumptions are needed, especially for countries where data are sparse. The data representativeness index (that is, the percentage of locations with data for a given time period) for IKF in 2007-2017 was only 28.5% 5 . In addition, estimating the impact of CKD as a condition depends on the validity of ICD coding, particularly when categorized into disease subtypes, and health survey data, which is widely used for CKD prevalence estimation, are largely based on eGFR and ACR without specifying underlying cause 7 . In Europe, substantial inter-country variation in CKD prevalence was not explained by the prevalence of diabetes, hypertension or obesity 7 .This variation is more likely related to social, environmental and genetic factors than to survey and laboratory assay issues, but such risks are not explicitly captured in the GBD study.
Despite some uncertainties in the data assumptions, the latest GBD study highlights the growing absolute burden of CKD across all regions, largely driven by population ageing, and a global rise in metabolic risk factors (particularly obesity), especially in Latin America-Caribbean, North Africa-Middle East, and Oceania. These trends dictate that policies and practices should focus on increasing the effectiveness
